Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | CITADEL-101 study- Parsaclisib in R/R B-cell malignancies

Tycel Phillips, MD, of the University of Michigan, Ann Arbor, MI, discusses the CITADEL-101 trial (NCT02018861) investigating the maximum tolerated dose or pharmacologic active dose of a PI3Kδ inhibitor, parsaclisib, as monotherapy and in combination with itacitinib, This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.